CA3109702A1 - Peptides et compositions pour traitement et imagerie cibles - Google Patents

Peptides et compositions pour traitement et imagerie cibles Download PDF

Info

Publication number
CA3109702A1
CA3109702A1 CA3109702A CA3109702A CA3109702A1 CA 3109702 A1 CA3109702 A1 CA 3109702A1 CA 3109702 A CA3109702 A CA 3109702A CA 3109702 A CA3109702 A CA 3109702A CA 3109702 A1 CA3109702 A1 CA 3109702A1
Authority
CA
Canada
Prior art keywords
trem
cancer
inhibitor
group
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3109702A
Other languages
English (en)
Inventor
Alexander B. Sigalov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signablok Inc
Original Assignee
Signablok Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signablok Inc filed Critical Signablok Inc
Publication of CA3109702A1 publication Critical patent/CA3109702A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des compositions et des procédés de traitement du cancer et d'autres maladies liées à des cellules immunes activées à l'aide de modulateurs de voie de signalisation TREM-1/DAP-12. Les compositions, incluant des peptides et des variantes de peptides, modulent une réponse immunologique mandatée par TREM-1 en tant que régime de traitement autonome et par combinaison de traitements thérapeutiques. La présente invention concerne en outre des procédés pour prédire l'efficacité de thérapies modulatoires de TREM-1 sur des patients. Dans un mode de réalisation, la présente invention concerne le traitement ciblé, la prévention ciblée et/ou la détection ciblée du cancer incluant, entre autres, le cancer du poumon incluant un cancer du poumon non à petites cellules, le cancer du pancréas, une tumeur de cellule géante de la gaine de tendon, une tumeur de cellules géantes ténosynoviales, une synovite villonodulaire pigmentée, une cachexie cancéreuse, etc., et d'autres cancers associés à l'activation et au recrutement de cellules myéloïdes. De plus, la présente invention concerne le traitement ciblé, la prévention ciblée et/ou la détection ciblée d'une sclérodermie incluant, entre autres, la calcinose, le phénomène de Raynaud, une dysmotilité sophagienne, une sclérodermie, ou un syndrome de télangiectasie (CREST). La présente invention concerne en outre des traitements médicaux personnalisés.
CA3109702A 2018-08-13 2019-08-13 Peptides et compositions pour traitement et imagerie cibles Pending CA3109702A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862717929P 2018-08-13 2018-08-13
US62/717,929 2018-08-13
US201862751303P 2018-10-26 2018-10-26
US62/751,303 2018-10-26
US201962836823P 2019-04-22 2019-04-22
US62/836,823 2019-04-22
US201962843835P 2019-05-06 2019-05-06
US62/843,835 2019-05-06
US201962875287P 2019-07-17 2019-07-17
US62/875,287 2019-07-17
PCT/US2019/046392 WO2020036987A1 (fr) 2018-08-13 2019-08-13 Peptides et compositions pour traitement et imagerie ciblés

Publications (1)

Publication Number Publication Date
CA3109702A1 true CA3109702A1 (fr) 2020-02-20

Family

ID=67957375

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3109702A Pending CA3109702A1 (fr) 2018-08-13 2019-08-13 Peptides et compositions pour traitement et imagerie cibles

Country Status (3)

Country Link
EP (1) EP3836951A1 (fr)
CA (1) CA3109702A1 (fr)
WO (1) WO2020036987A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230097095A (ko) * 2020-10-30 2023-06-30 더 제너럴 하스피탈 코포레이션 간 질환의 평가를 위한 키트, 시약 및 방법
CA3218327A1 (fr) * 2021-05-19 2022-11-24 Alexander Sigalov Inhibiteurs de trem-2/dap-12 pour traiter des maladies et des lesion pulmonaires et combinaisons de ceux-ci

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
CN1124964A (zh) 1993-06-11 1996-06-19 默里尔药物公司 三功能抗凝血酶和抗血小板的肽
WO1996022306A1 (fr) 1995-01-16 1996-07-25 Northern Sydney Area Health Service Nouveau peptide
AU739130B2 (en) 1996-06-11 2001-10-04 Northern Sydney And Central Coast Area Health Service T cell antigen receptor peptides
US20050070478A1 (en) 1996-06-11 2005-03-31 Northern Sydney Area Health Services T cell antigen receptor peptides
EP1351702B1 (fr) * 2000-12-08 2015-03-04 Bioprovar Corporation Variant d'épissage de Trem-1 utile pour modifier des réactions immunitaires
CA2342376C (fr) * 2001-03-20 2013-11-12 Marco Colonna Nouveau recepteur trem (recepteur activateur exprime dans les cellules myeloides) et ses utilisations
RU2316349C2 (ru) 2001-05-02 2008-02-10 Пердью Рисерч Фаундейшн Лечение и диагностика заболеваний, опосредованных макрофагами
EP2306192B1 (fr) 2003-12-05 2015-10-14 The Cleveland Clinic Foundation Marqueurs de risque pour maladies cardiovasculaires
GB0401730D0 (en) 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CA2626238C (fr) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Peptides de liaison wt1 hla de classe ii, compositions et methodes associees comprenant ces peptides
US20080293795A1 (en) 2006-01-17 2008-11-27 Abbott Laboratories Combination therapy with parp inhibitors
JP4087420B2 (ja) 2006-06-28 2008-05-21 シャープ株式会社 画像表示装置、画像データ送信装置、画像表示システム、画像表示方法、画像表示プログラムおよびその記録媒体、並びに、画像データ送信プログラムおよびその記録媒体
US7972794B2 (en) 2006-07-18 2011-07-05 Quest Diagnostics Investments Incorporated Oxidized apoA-I determination by mass spectrometry
US8496942B2 (en) 2006-12-13 2013-07-30 Susavion Biosciences, Inc. Therapeutic peptides and uses thereof
US8278271B2 (en) 2006-12-13 2012-10-02 University Of Massachusetts Inhibiting collagen-induced platelet aggregation and activation with peptide variants
US7811995B2 (en) 2006-12-13 2010-10-12 Susavion Biosciences, Inc. Therapeutic and diagnostic peptides
US20080247955A1 (en) 2007-01-16 2008-10-09 Jun Kuai Inflammation treatment, detection and monitoring via TREM-1
US8415453B2 (en) 2007-02-13 2013-04-09 Academia Sinica Lung cancer-targeted peptides and applications thereof
CA3102704A1 (fr) 2007-12-14 2009-06-25 Novo Nordisk A/S Anticorps humains anti-nkg2d et leurs utilisations
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
WO2010043047A1 (fr) 2008-10-15 2010-04-22 Angiochem Inc. Conjugués d'agonistes de glp-1 et leurs utilisations
WO2010057275A1 (fr) 2008-11-24 2010-05-27 Sydney West Area Health Services Peptides cycliques et leurs utilisations
US8680139B2 (en) 2009-04-01 2014-03-25 Progenra Anti-neoplastic compounds, compositions and methods
JP2012524030A (ja) 2009-04-20 2012-10-11 アンジオケム インコーポレーテッド Ａｎｇｉｏｐｅｐ−２アナログにコンジュゲート化した抗癌剤を用いた卵巣癌の治療
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
NZ597470A (en) 2009-07-13 2013-11-29 Univ Surrey Therapeutic peptides, polypeptides ans nucleic acid sequences
US10138276B2 (en) 2009-09-30 2018-11-27 Signablok, Inc. Inhibition of TCR signaling with peptide variants
WO2011044545A2 (fr) 2009-10-09 2011-04-14 Sigalov Alexander B Procédés et compositions pour une imagerie ciblée
US8513185B2 (en) 2009-10-13 2013-08-20 Alexander B. Sigalov Inhibition of TREM receptor signaling with peptide variants
AU2011237851B2 (en) 2010-04-08 2015-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibiting peptides derived from TREM-Like Transcript 1 (TLT-1) and uses thereof
DK2704713T3 (en) 2011-05-05 2017-04-24 Novartis Ag CSF-1R inhibitors for the treatment of brain tumors
EP3196214B1 (fr) 2012-02-15 2019-07-31 Novo Nordisk A/S Anticorps liant et bloquant un récepteur de déclenchement exprimé sur des cellules-1 myéloïdes (trem-1)
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
CA2884121C (fr) 2012-09-07 2021-10-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Peptides inhibiteurs issus du transcrit 1 de type trem, recepteur de declenchement exprime sur des cellules myeloides 1 (trem-1), (tlt-1) et leurs utilisations
MX2015011984A (es) 2013-03-12 2015-12-15 Abbvie Inc Inhibidores de bromodominio de dihidro-pirrolopiridinona.
US9387257B2 (en) 2014-01-17 2016-07-12 Academia Sinica Lung cancer specific peptides for targeted drug delivery and molecular imaging
BR112017013111A2 (pt) 2014-12-22 2018-05-15 Five Prime Therapeutics Inc métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
US9717717B1 (en) 2015-07-31 2017-08-01 Progenra, Inc. Methods of treating cancer through the inhibition of USP7 and immune system modulation
US11213598B2 (en) 2015-11-12 2022-01-04 The Board Of Trustees Of The Leland Stanford Junior University Labeled probe and methods of use

Also Published As

Publication number Publication date
WO2020036987A1 (fr) 2020-02-20
EP3836951A1 (fr) 2021-06-23

Similar Documents

Publication Publication Date Title
JP5474535B2 (ja) Ｆｋｂｐ−ｌおよびその使用
ES2928111T3 (es) Inhibición de la señalización AXL en terapia antimetastásica
AU2019293600A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
US20240076379A1 (en) Antibodies to programmed cell death protein 1
US20210363240A1 (en) Compositions and methods for modulating lair signal transduction
KR20090071598A (ko) 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
CN111718424A (zh) 单链trail受体激动剂蛋白
US20190388505A1 (en) Methods and compositions for immunomodulation
AU2018283161A1 (en) Renal-homing peptide conjugates and methods of use thereof
JP2023504286A (ja) 薬物送達のためのデンドリマー組成物および方法
Park et al. PEGylated TRAIL ameliorates experimental inflammatory arthritis by regulation of Th17 cells and regulatory T cells
WO2020052570A1 (fr) Méthode et composition destinées à la prévention et au traitement de l'athérosclérose et de maladies associées
CA3109702A1 (fr) Peptides et compositions pour traitement et imagerie cibles
WO2017082186A1 (fr) Nouvelle utilisation pour agoniste de npr-a
US20240226306A1 (en) Trem-2/dap-12 inhibitors for treating lung disease and injury and combinations thereof
US20210322508A1 (en) Peptides and compositions for targeted treatment and imaging
KR20240056684A (ko) 혈관활성 장 펩티드(vip) 수용체 길항제
EP1501535A1 (fr) Antagonistes de megaline ou de cubiline destines a etre utilises dans la prevention de l'endommagement d'organes induit par des agents therapeutiques
JP2003525628A (ja) プロテインチロシンホスファターゼポリヌクレオチド、ポリペプチド、および抗体
US7345018B2 (en) Method of treating side effects induced by therapeutic agents
TW202132334A (zh) Ｃｘｃｒ４拮抗劑肽
WO2012122943A1 (fr) Médicament contre la protéine x du virus de l'hépatite b utlisant un polypeptide
Li et al. T cell/Macrophage Dual-Targeting Biomimetic Triptolide Self-Assembly Nanodrugs For Rheumatoid Arthritis Therapy by Inflammatory Microenvironment Remodeling
Wagner Investigation of a novel small molecule TRAIL inducer, ONC201: pre-clinical anti-cancer efficacy, anti-metastasis effects, tumor immunity; and the structure-activity relationships (SAR) and mechanism of action of potential analogues
WO2021021276A1 (fr) Administration prolongée, ajustable, multiciblée de charges utiles à des tissus avasculaires chargés

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220614

EEER Examination request

Effective date: 20220614

EEER Examination request

Effective date: 20220614

EEER Examination request

Effective date: 20220614

EEER Examination request

Effective date: 20220614

EEER Examination request

Effective date: 20220614